vs
Side-by-side financial comparison of CytomX Therapeutics, Inc. (CTMX) and NATIONAL BANKSHARES INC (NKSH). Click either name above to swap in a different company.
CytomX Therapeutics, Inc. is the larger business by last-quarter revenue ($18.7M vs $15.3M, roughly 1.2× NATIONAL BANKSHARES INC). NATIONAL BANKSHARES INC runs the higher net margin — 38.5% vs -0.8%, a 39.3% gap on every dollar of revenue. On growth, NATIONAL BANKSHARES INC posted the faster year-over-year revenue change (24.7% vs -25.7%). NATIONAL BANKSHARES INC produced more free cash flow last quarter ($15.2M vs $-15.8M). Over the past eight quarters, NATIONAL BANKSHARES INC's revenue compounded faster (20.9% CAGR vs -15.9%).
CytomX Therapeutics is a clinical-stage biotechnology company specializing in innovative cancer immunotherapies. It leverages its proprietary Probody technology platform to develop targeted therapies that activate exclusively in tumor microenvironments, minimizing off-target toxicities, with a pipeline covering multiple solid tumor indications and partnerships with leading global pharmaceutical firms.
Nicolet Bankshares, Inc. is a U.S. regional bank holding company based in Green Bay, Wisconsin. They are the parent company of Nicolet National Bank, the second largest Wisconsin-based bank.
CTMX vs NKSH — Head-to-Head
Income Statement — Q2 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $18.7M | $15.3M |
| Net Profit | $-154.0K | $5.9M |
| Gross Margin | — | — |
| Operating Margin | -6.9% | 47.4% |
| Net Margin | -0.8% | 38.5% |
| Revenue YoY | -25.7% | 24.7% |
| Net Profit YoY | 97.6% | 91.0% |
| EPS (diluted) | — | $0.93 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $15.3M | ||
| Q3 25 | — | $14.2M | ||
| Q2 25 | $18.7M | $13.3M | ||
| Q1 25 | $50.9M | $12.8M | ||
| Q4 24 | $38.1M | $12.2M | ||
| Q3 24 | $33.4M | $11.7M | ||
| Q2 24 | $25.1M | $10.9M | ||
| Q1 24 | $41.5M | $10.4M |
| Q4 25 | — | $5.9M | ||
| Q3 25 | — | $4.4M | ||
| Q2 25 | $-154.0K | $2.3M | ||
| Q1 25 | $23.5M | $3.2M | ||
| Q4 24 | $18.9M | $3.1M | ||
| Q3 24 | $5.7M | $2.7M | ||
| Q2 24 | $-6.5M | $-307.0K | ||
| Q1 24 | $13.8M | $2.2M |
| Q4 25 | — | 47.4% | ||
| Q3 25 | — | 37.9% | ||
| Q2 25 | -6.9% | 20.0% | ||
| Q1 25 | 44.4% | 30.5% | ||
| Q4 24 | 46.4% | 30.1% | ||
| Q3 24 | 12.3% | 27.5% | ||
| Q2 24 | -33.7% | -4.4% | ||
| Q1 24 | 28.1% | 25.8% |
| Q4 25 | — | 38.5% | ||
| Q3 25 | — | 31.1% | ||
| Q2 25 | -0.8% | 17.2% | ||
| Q1 25 | 46.2% | 25.3% | ||
| Q4 24 | 49.6% | 25.1% | ||
| Q3 24 | 17.2% | 22.8% | ||
| Q2 24 | -26.0% | -2.8% | ||
| Q1 24 | 33.3% | 20.8% |
| Q4 25 | — | $0.93 | ||
| Q3 25 | — | $0.69 | ||
| Q2 25 | — | $0.36 | ||
| Q1 25 | — | $0.51 | ||
| Q4 24 | — | $0.50 | ||
| Q3 24 | — | $0.42 | ||
| Q2 24 | — | $-0.05 | ||
| Q1 24 | — | $0.37 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $49.0M | $59.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $119.9M | $184.9M |
| Total Assets | $175.1M | $1.8B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $59.3M | ||
| Q3 25 | — | $42.3M | ||
| Q2 25 | $49.0M | $92.8M | ||
| Q1 25 | $47.6M | $122.5M | ||
| Q4 24 | $38.1M | $108.1M | ||
| Q3 24 | $40.6M | $49.8M | ||
| Q2 24 | $43.2M | $98.9M | ||
| Q1 24 | $36.2M | $121.2M |
| Q4 25 | — | $184.9M | ||
| Q3 25 | — | $179.2M | ||
| Q2 25 | $119.9M | $168.7M | ||
| Q1 25 | $25.0M | $167.3M | ||
| Q4 24 | $-456.0K | $156.4M | ||
| Q3 24 | $-23.5M | $167.8M | ||
| Q2 24 | $-31.2M | $149.0M | ||
| Q1 24 | $-31.7M | $139.4M |
| Q4 25 | — | $1.8B | ||
| Q3 25 | — | $1.8B | ||
| Q2 25 | $175.1M | $1.8B | ||
| Q1 25 | $98.5M | $1.8B | ||
| Q4 24 | $120.5M | $1.8B | ||
| Q3 24 | $139.0M | $1.8B | ||
| Q2 24 | $159.2M | $1.8B | ||
| Q1 24 | $184.7M | $1.7B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-15.8M | $17.9M |
| Free Cash FlowOCF − Capex | $-15.8M | $15.2M |
| FCF MarginFCF / Revenue | -84.6% | 99.2% |
| Capex IntensityCapex / Revenue | 0.1% | 17.9% |
| Cash ConversionOCF / Net Profit | — | 3.04× |
| TTM Free Cash FlowTrailing 4 quarters | $-77.7M | $23.6M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $17.9M | ||
| Q3 25 | — | $6.1M | ||
| Q2 25 | $-15.8M | $2.1M | ||
| Q1 25 | $-21.0M | $2.6M | ||
| Q4 24 | $-19.9M | $9.4M | ||
| Q3 24 | $-20.7M | $3.1M | ||
| Q2 24 | $-19.5M | $-3.0M | ||
| Q1 24 | $-26.0M | $3.8M |
| Q4 25 | — | $15.2M | ||
| Q3 25 | — | $5.3M | ||
| Q2 25 | $-15.8M | $1.5M | ||
| Q1 25 | $-21.2M | $1.6M | ||
| Q4 24 | $-20.0M | $6.2M | ||
| Q3 24 | $-20.7M | $2.2M | ||
| Q2 24 | $-19.6M | $-4.0M | ||
| Q1 24 | $-26.2M | $3.5M |
| Q4 25 | — | 99.2% | ||
| Q3 25 | — | 37.4% | ||
| Q2 25 | -84.6% | 11.5% | ||
| Q1 25 | -41.6% | 12.5% | ||
| Q4 24 | -52.5% | 50.5% | ||
| Q3 24 | -62.1% | 18.5% | ||
| Q2 24 | -78.2% | -36.3% | ||
| Q1 24 | -63.1% | 33.8% |
| Q4 25 | — | 17.9% | ||
| Q3 25 | — | 5.6% | ||
| Q2 25 | 0.1% | 4.1% | ||
| Q1 25 | 0.2% | 7.5% | ||
| Q4 24 | 0.2% | 26.6% | ||
| Q3 24 | 0.1% | 8.3% | ||
| Q2 24 | 0.4% | 9.3% | ||
| Q1 24 | 0.3% | 3.0% |
| Q4 25 | — | 3.04× | ||
| Q3 25 | — | 1.38× | ||
| Q2 25 | — | 0.90× | ||
| Q1 25 | -0.89× | 0.79× | ||
| Q4 24 | -1.05× | 3.07× | ||
| Q3 24 | -3.61× | 1.17× | ||
| Q2 24 | — | — | ||
| Q1 24 | -1.89× | 1.77× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CTMX
| Bristol Myers Squibb Company | $11.6M | 62% |
| Astellas Pharma Inc | $4.6M | 25% |
| Regeneron Pharmaceuticals Inc | $2.1M | 11% |
NKSH
Segment breakdown not available.
